{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:16:40Z","timestamp":1793236600716,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clgc.2024.102238","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T01:24:42Z","timestamp":1729128282000},"page":"102238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II Study"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-3394","authenticated-orcid":false,"given":"Petros","family":"Grivas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-2951","authenticated-orcid":false,"given":"Pedro","family":"Barata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora N.","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-7555","authenticated-orcid":false,"given":"Jason R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaidehi","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia C.","family":"Shillington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5314-2972","authenticated-orcid":false,"given":"Howard M.","family":"Katzenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Kirker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank X.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0355-7379","authenticated-orcid":false,"given":"Valerie","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet","family":"Bhanegaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1010-9611","authenticated-orcid":false,"given":"Guru P.","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.102238_bib0001","unstructured":"National Cancer Institute. SEER Cancer Stat Facts: Bladder Cancer. Accessed August 12, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html."},{"key":"10.1016\/j.clgc.2024.102238_bib0002","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.clgc.2024.102238_bib0003","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1200\/JCO.22.02763","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"41","author":"von der Maase","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102238_bib0004","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102238_bib0005","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102238_bib0006","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102238_bib0007","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102238_bib0008","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102238_bib0009","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2023.03.030","article-title":"Avelumab first-line maintenance therapy for advanced urothelial carcinoma: comprehensive clinical subgroup analyses from the JAVELIN Bladder 100 phase 3 trial","volume":"84","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102238_bib0010","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.eururo.2023.08.001","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: analysis from JAVELIN Bladder 100 by duration of first-line chemotherapy and interval before maintenance","volume":"85","author":"Sridhar","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102238_bib0011","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2022.04.016","article-title":"Patient-reported outcomes from JAVELIN Bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma","volume":"83","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102238_bib0012","unstructured":"EMOL Health. The successful integration of information technology and patient-based oncology data. Accessed March 5, 2024. https:\/\/learnmore.emolhealth.com\/."},{"key":"10.1016\/j.clgc.2024.102238_bib0013","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.clgc.2023.03.011","article-title":"Evaluating real-world characteristics of patients with advanced urothelial carcinoma eligible for avelumab maintenance therapy: a multicountry retrospective medical chart review","volume":"21","author":"Bellmunt","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2024.102238_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.508","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy","volume":"41","author":"Sridhar","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102238_bib0015","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.clgc.2023.06.008","article-title":"Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients with advanced urothelial carcinoma (aUC): \"real world\" experience","volume":"21","author":"Bakaloudi","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2024.102238_bib0016","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.605","article-title":"Real-world (rw) treatment patterns, sequencing, and outcomes in patients (pts) with locally advanced or metastatic urothelial carcinoma (la\/mUC) receiving avelumab first-line maintenance (1LM) in the US","volume":"42","author":"Moon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102238_bib0017","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.561","article-title":"Updated results from AVENANCE: real-world effectiveness of avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) and analysis of subsequent treatment","volume":"42","author":"Barthelemy","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102238_bib0018","article-title":"READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma","volume":"5","author":"Antonuzzo","year":"2024","journal-title":"ESMO Real World Data Digi Oncol"},{"key":"10.1016\/j.clgc.2024.102238_bib0019","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jjco\/hyac186","article-title":"Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study","volume":"53","author":"Miyake","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102238_bib0020","unstructured":"Park SH, Rah SY, Seo HK, Keam B, Oh ES, Lee J-L. First results of a Korean expanded access program of avelumab first-line maintenance in patients with locally advanced or metastatic urothelial carcinoma. Poster presented at 15th Annual Meeting of the Korean Society of Medical Oncology & 2022 International Congress; Seoul, Korea; September 1-2. 2022."},{"key":"10.1016\/j.clgc.2024.102238_bib0021","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102238_bib0022","article-title":"Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study","volume":"42","author":"Nizam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102238_bib0023","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1038\/s41591-021-01579-0","article-title":"Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial","volume":"27","author":"Powles","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2024.102238_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1028","article-title":"AVENANCE: subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)","volume":"34","author":"Barthelemy","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2024.102238_bib0025","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/oncolo\/oyad174","article-title":"Clinical and economic outcomes in patients with metastatic urothelial carcinoma receiving first-line systemic treatment (the IMPACT UC I study)","volume":"28","author":"Bilen","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2024.102238_bib0026","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.2217\/fon-2019-0434","article-title":"Healthcare resource utilization and costs of adverse events among patients with metastatic urothelial cancer in USA","volume":"15","author":"Grivas","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2024.102238_bib0027","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2024.102238_bib0028","series-title":"Bristol-Myers Squibb","article-title":"Prescribing information","author":"Opdivo (nivolumab)","year":"2024"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:30:42Z","timestamp":1762551042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324002088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1558767324002088"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102238","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102238","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102238"}}